📰 Updated Analysis News
Page 2 - Updated Analysis News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Updated Analysis. Real-time updates on events, politics, business and more.
May 12, 2022
Multiple epcoritamab (DuoBody-CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient populations in need of treatment options Several
April 4, 2022
Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm high
April 4, 2022
Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every...
February 18, 2022
It is not known at this time if this year's report to Congress will alter the projected year of HI depletion./ 2. The decline of HI's reserves is of course, on its own, a problem that should concern Congress because of the importance of ensuring continuity in the provision of medical services. Congress has never allowed such a scenario to occur, and it is unlikely to do...
December 11, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with...
December 11, 2021
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with...
December 11, 2021
Investigational daratumumab quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients with multiple myeloma in randomised Phase 2 GRIFFIN study1 Real-world...
December 11, 2021
Investigational daratumumab quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients with multiple myeloma in randomised Phase 2 GRIFFIN study1 Real-world evidence
November 4, 2021
Poster presentations highlighting safety and preliminary efficacy data of epcoritamab (DuoBody-CD3xCD20) in combination with other treatments in patients with B-cell non-Hodgkin lymphoma (NHL)
October 13, 2021
Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower